Insurance must cover Bioidentical hormones as they do pharmaceutical one
Summary
HB 4075 would require health insurance coverage for bioidentical hormones on the same basis as pharmaceutical hormone products. Based on the caption, the bill appears aimed at preventing insurers from treating bioidentical hormone therapy differently from comparable prescription hormone treatments, likely by mandating parity in coverage terms, access, or reimbursement. Because the bill text was not available in the provided materials, the precise statutory changes and definitions are not visible here, but the measure is clearly focused on insurance coverage for hormone therapy.
If enacted, the bill would likely affect state insurance law by directing insurers subject to West Virginia regulation to cover bioidentical hormone treatments similarly to other hormone medications. The practical effect would be on health plans, insurers, and patients who use hormone therapy, potentially including treatments associated with menopause care, endocrine disorders, or gender-affirming care depending on how the term is defined in implementation. The bill was referred to House Finance, suggesting it may have fiscal or coverage-cost implications for the state or regulated plans.
Impact
The bill would likely amend West Virginia insurance coverage requirements to prohibit differential treatment of bioidentical hormones compared with pharmaceutical hormone products. This could affect insurers, health benefit plans, and pharmacy benefit managers by requiring broader or more uniform coverage for hormone therapy products and related prescriptions. The exact scope would depend on definitions and enforcement provisions not available in the provided text.
Sentiment
The available record does not include committee testimony or recorded votes, so there is no direct evidence of debate or opposition in the materials provided. The caption suggests the bill is intended to expand or equalize insurance coverage, which typically draws support from patients and advocates seeking access to specific therapies. Referral to House Finance indicates the bill may have been viewed as having cost or coverage implications, but no formal sentiment can be inferred beyond that.
Contention
No specific points of contention are documented in the provided transcripts or vote history. Potential areas of dispute, based on the subject matter, would likely include whether bioidentical hormones should be treated differently from other hormone therapies, the cost impact on insurers and premiums, and how broadly the coverage mandate should apply. Without committee discussion, it is not possible to identify which stakeholders raised these concerns, if any.
Relating to liability or other insurance coverage provided by the Board of Risk and Insurance Management to any entity for which such coverage is permissive under state code